14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Structure-Guided Design of a Fluorescent Probe for the Visualization of FtsZ in Clinically Important Gram-Positive and Gram-Negative Bacterial Pathogens

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Addressing the growing problem of antibiotic resistance requires the development of new drugs with novel antibacterial targets. FtsZ has been identified as an appealing new target for antibacterial agents. Here, we describe the structure-guided design of a new fluorescent probe ( BOFP) in which a BODIPY fluorophore has been conjugated to an oxazole-benzamide FtsZ inhibitor. Crystallographic studies have enabled us to identify the optimal position for tethering the fluorophore that facilitates the high-affinity FtsZ binding of BOFP. Fluorescence anisotropy studies demonstrate that BOFP binds the FtsZ proteins from the Gram-positive pathogens Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus pneumoniae with K d values of 0.6–4.6 µM. Significantly, BOFP binds the FtsZ proteins from the Gram-negative pathogens Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii with an even higher affinity (K d = 0.2–0.8 µM). Fluorescence microscopy studies reveal that BOFP can effectively label FtsZ in all the above Gram-positive and Gram-negative pathogens. In addition, BOFP is effective at monitoring the impact of non-fluorescent inhibitors on FtsZ localization in these target pathogens. Viewed as a whole, our results highlight the utility of BOFP as a powerful tool for identifying new broad-spectrum FtsZ inhibitors and understanding their mechanisms of action.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance

          The increasing use of polymyxins 1 in addition to the dissemination of plasmid-borne colistin resistance threatens to cause a serious breach in our last line of defense against multidrug resistant Gram-negative pathogens, and heralds the emergence of truly pan-resistant infections. Colistin resistance often arises through covalent modification of lipid A with cationic residues such as phosphoethanolamine (PEtN) – as is mediated by Mcr-1 2 – which reduce the affinity of polymyxins for lipopolysaccharide (LPS) 3 . Thus, new strategies are needed to address the rapidly diminishing number of treatment options for Gram-negative infections 4 . The difficulty in eradicating Gram-negative bacteria is largely due to a highly impermeable outer membrane, which serves as a barrier to many otherwise effective antibiotics 5 . Here, we describe an unconventional screening platform designed to enrich for non-lethal, outer membrane-active compounds with potential as adjuvants for conventional antibiotics. This approach identified the antiprotozoal drug pentamidine 6 as an effective perturbant of the Gram-negative outer membrane through its interaction with LPS. Pentamidine displayed synergy with antibiotics typically restricted to Gram-positive bacteria, yielding effective drug combinations with activity against a wide range of Gram-negative pathogens in vitro, and against systemic Acinetobacter baumannii infections in mice. Notably, the adjuvant activity of pentamidine persisted in polymyxin resistant bacteria in vitro and in vivo. Overall, pentamidine and structural analogs represent unexploited molecules for the treatment of Gram-negative infections, particularly those having acquired polymyxin resistance determinants.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.

            FtsZ is an essential bacterial guanosine triphosphatase and homolog of mammalian beta-tubulin that polymerizes and assembles into a ring to initiate cell division. We have created a class of small synthetic antibacterials, exemplified by PC190723, which inhibits FtsZ and prevents cell division. PC190723 has potent and selective in vitro bactericidal activity against staphylococci, including methicillin- and multi-drug-resistant Staphylococcus aureus. The putative inhibitor-binding site of PC190723 was mapped to a region of FtsZ that is analogous to the Taxol-binding site of tubulin. PC190723 was efficacious in an in vivo model of infection, curing mice infected with a lethal dose of S. aureus. The data validate FtsZ as a target for antibacterial intervention and identify PC190723 as suitable for optimization into a new anti-staphylococcal therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cell-division inhibitors: new insights for future antibiotics.

              The growing problem of antibiotic resistance has been exacerbated by the use of new drugs that are merely variants of older overused antibiotics. While it is naive to expect to restrain the spread of resistance without controlling antibacterial usage, the desperate need for drugs with novel targets has been recognized by health organizations, industry and academia alike. The wealth of knowledge available about the bacterial cell-division pathway has aided target-driven approaches to identify novel inhibitors. Here, we discuss the therapeutic potential of inhibiting bacterial cell division, and review the progress made in this exciting new area of antibacterial discovery.
                Bookmark

                Author and article information

                Contributors
                h-matsu@fc.ritsumei.ac.jp
                pilchds@rwjms.rutgers.edu
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                27 December 2019
                27 December 2019
                2019
                : 9
                : 20092
                Affiliations
                [1 ]ISNI 0000 0004 1936 8796, GRID grid.430387.b, Department of Pharmacology, , Rutgers Robert Wood Johnson Medical School, ; 675 Hoes Lane, Piscataway, NJ 08854 USA
                [2 ]ISNI 0000 0004 0373 3971, GRID grid.136593.b, Department of Applied Chemistry, , Graduate School of Engineering, Osaka University, ; 2-1 Yamadaoka, Suita, Osaka 565-087 Japan
                [3 ]ISNI 0000 0000 8863 9909, GRID grid.262576.2, Department of Biotechnology, College of Life Sciences, Ritsumeikan University, ; 1-1-1 Noji-Higashi, Shiga, 525-8577 Japan
                [4 ]ISNI 0000 0004 1936 8796, GRID grid.430387.b, Department of Biochemistry and Microbiology, School of Environmental and Biological Sciences, Rutgers University, ; 76 Lipman Drive, New Brunswick, NJ 08901 USA
                [5 ]ISNI 0000 0004 1936 8796, GRID grid.430387.b, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, ; 160 Frelinghuysen Road, Piscataway, NJ 08854 USA
                [6 ]Present Address: MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0QH UK
                Author information
                http://orcid.org/0000-0003-1273-3917
                http://orcid.org/0000-0002-0113-0849
                Article
                56557
                10.1038/s41598-019-56557-x
                6934700
                31882782
                9364e169-9770-4e29-8f60-54ac1a90afad
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 24 September 2019
                : 11 December 2019
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100001691, MEXT | Japan Society for the Promotion of Science (JSPS);
                Award ID: 15J00589
                Award ID: 19K16060
                Award ID: 17H05732, 18K06094, 19H04735, 19K07582
                Award ID: 17H05732, 18K06094, 19H04735, 19K07582
                Award ID: 17H05732, 18K06094, 19H04735, 19K07582
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/100000002, U.S. Department of Health & Human Services | National Institutes of Health (NIH);
                Award ID: AI118874
                Award ID: AI118874
                Award Recipient :
                Funded by: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                Uncategorized
                antibiotics,phenotypic screening
                Uncategorized
                antibiotics, phenotypic screening

                Comments

                Comment on this article